Insulet (PODD) and Its Rivals Head-To-Head Comparison

Insulet (NASDAQ: PODD) is one of 106 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Insulet to similar companies based on the strength of its earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Insulet and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet 0 4 15 0 2.79
Insulet Competitors 537 1984 3882 134 2.55

Insulet presently has a consensus price target of $87.75, indicating a potential upside of 0.23%. As a group, “Surgical & medical instruments” companies have a potential upside of 3.83%. Given Insulet’s peers higher possible upside, analysts clearly believe Insulet has less favorable growth aspects than its peers.

Profitability

This table compares Insulet and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Insulet -4.82% -20.02% -3.60%
Insulet Competitors -74.52% -78.80% -19.20%

Earnings and Valuation

This table compares Insulet and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Insulet $463.77 million -$26.83 million -190.33
Insulet Competitors $1.51 billion $110.21 million -202.84

Insulet’s peers have higher revenue and earnings than Insulet. Insulet is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Insulet has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Insulet’s peers have a beta of 0.77, indicating that their average share price is 23% less volatile than the S&P 500.

Institutional & Insider Ownership

46.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 3.6% of Insulet shares are owned by company insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Insulet beats its peers on 7 of the 13 factors compared.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit